Pasar al contenido principal

ONCOPROTEINAS DE LA FAMILIA VAV: REGULACION, FUNCIONES PATOFISIOLOGICAS Y POTENCIAL TERAPEUTICO

SAF2015-64556-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2015
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Dirección General de Investigación Científica y Técnica
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Genetic analysis of the role of vav oncoproteins in cancer

  • Bustelo, Xosé R.
  • Cuadrado, Myriam
  • Robles-Valero, Javier
  • Lorenzo-Martín, L. Francisco
Trabajo presentado en el Meeting Small G proteins in cellular signalling and disease, celebrado en Cambridge (Reino Unido) del 09 al 12 de julio de 2018., Rho GDP/GTP exchange factors (GEFs) are enzymes that promote the activation of Rho GTPases in both normal and cancer cells. Due to this, it is widely assumed that they can represent potential anticancer drug targets. However, we still have very little information about the actual role of these enzymes in human cancer, the therapeutic effectiveness of inhibiting their enzyme activities, and the side effects that such inhibition elicits in healthy tissues. Our group is trying to address these issues using as main tool the three known members of the Vav GEF family, the proteins Vav1, Vav2 and Vav3. To this end, we are utilizing a multifaceted approach based on the use of genetically modified mice, genome wide expression profiling techniques, cross-species transcriptomal comparisons, and patient-derived cell models. In my talk, I will present recent data demonstrating that the endogenous wild type and mutant versions of these proteins play proactive roles in mature T cell leukemia and a variety of epithelial tumors. Furthermore, I will discuss data from our “pharmaco-mimetic” knock-in mice demonstrating that the inhibition of GEFs does have a negative impact on the fitness of tumor cells in vivo., This work has been supported by grants from the Spanish Ministry of Economy and Competitiveness (SAF2015-64556-R), the Castilla-León Government (CSI049U16), Worldwide Cancer Research (14-1248), Ramón Areces Foundation, and the Spanish Association against Cancer (GC16173472GARC).